Recent preclinical studies suggest that combining EGFR kinase inhibitors and anti-EGFR antibodies may be more effective than either alone, perhaps because EGFR is able to maintain cancer cell survival independent of its kinase activity [17-19]. This evidence concerns the gene EGFR and cancer.